The T2DM drugs metformin, SGLT2 inhibitors, DPP-IV inhibitors, and GLP-1 analogs may have the potential to treat aging-related skeletal muscle atrophy, but the reported clinical and pre-clinical data are currently inconclusive and require further investigation in models of muscle aging (Table 2). Here, SLC5A2 is linked to type 2 diabetes mellitus.